首页> 外文期刊>BMC Infectious Diseases >Use of laboratory and administrative data to understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada
【24h】

Use of laboratory and administrative data to understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada

机译:利用实验室和行政数据来了解人副流感病毒4对加拿大艾伯塔省的毛细支气管炎,人群和肺炎病例的潜在影响

获取原文
获取外文期刊封面目录资料

摘要

Background Human Parainfluenza Virus (hPIV) causes severe respiratory illness in infants and adults. Our study describes the association of hPIV1–4 with bronchiolitis, croup, and pneumonia using retrospective laboratory, administrative and public health data. Due to issues including the historic lack of hPIV4 in some commercial respiratory virus panels, the description of the impact of hPIV4 on croup, bronchiolitis, and pneumonia at population levels has often been limited. This study will use routine clinical laboratory data, and administrative data to provide a preliminary description of the impact of hPIV4 on these diseases in our population. Methods A three year cohort of patients positive for hPIV was linked with data from physician visits and hospital admissions to define cases and hospitalization status. International Classification of Disease (ICD-9) codes were used to determine if cases had croup, bronchiolitis, and pneumonia. We also looked at differences in hospitalization status, age and gender among hPIV1–4. All statistical analysis was done using SPSS (Version 19.0.0, IBM Corp? 2010) and Graphpad Prism V6 (GraphPad Software, Inc., 2012). Results Only hPIV1 and hPIV4 specimens had positivity rates greater than 5?% of all specimens sent for respiratory virus panel testing. hPIV1 exhibited a biennial pattern while the pattern for hPIV3 was less interpretable due to lower positivity rates. Circulation patterns for hPIV2 and hPIV4 were not assessed due to the low positivity rates of theses specimens. From 2010 to 2013, there were 2300 hPIV cases with hPIV3 (46?%) being the most common, followed by hPIV1 (27?%), hPIV4 (16?%) and hPIV2 (11?%). The median age was 2?years for all hPIV types. Males were slightly greater than females for hPIV1 and hPIV2, with an equal distribution for hPIV3 and slightly more females than males for hPIV4. hPIV1 and hPIV2 had the highest or proportion of croup while hPIV3 and hPIV4 had the highest proportion of pneumonia. Within hPIV4 cases, distributions of diseases were; pneumonia (21?%, 95 % CI 17.1–25.7), bronchiolitis (18?%, 95 % CI 14.3–22.5), croup (2?%, 95 % CI 0.8–3.9), mixed illness of any of pneumonia, bronchiolitis or croup (4?%, 95 % CI 2.5–7.0) or other respiratory diseases (54?%, 95 % CI 49.1–59.6). Conclusions We used laboratory and administrative data to undertake a descriptive analysis of the association of hPIV1–4 with croup, bronchiolitis and pneumonia. hPIV4 appears to be more associated more with bronchiolitis and pneumonia and less with croup in our population.
机译:背景技术人副流感病毒(hPIV)在婴儿和成人中引起严重的呼吸道疾病。我们的研究使用回顾性实验室,行政和公共卫生数据描述了hPIV1-4与毛细支气管炎,副反应性呼吸道炎和肺炎的关系。由于某些商业呼吸道病毒小组中历史上缺少hPIV4的问题,因此在人群水平上对hPIV4对人群,细支气管炎和肺炎的影响的描述往往受到限制。这项研究将使用常规的临床实验室数据和行政数据来初步描述hPIV4对这些人群中这些疾病的影响。方法将三年期hPIV阳性的患者队列与来自医生就诊和住院的数据联系起来,以确定病例和住院状态。使用国际疾病分类(ICD-9)代码来确定病例是否患有流行性腮腺炎,细支气管炎和肺炎。我们还研究了hPIV1-4之间住院状况,年龄和性别的差异。所有统计分析均使用SPSS(版本19.0.0,IBM Corp?2010)和Graphpad Prism V6(GraphPad Software,Inc.,2012)完成。结果只有hPIV1和hPIV4标本的阳性率高于送去呼吸道病毒检测的所有标本的5%。 hPIV1表现出两年一次的模式,而hPIV3的模式由于较低的阳性率而难以解释。由于这些样本的阳性率较低,因此未评估hPIV2和hPIV4的循环模式。从2010年到2013年,共有2300例hPIV病例,其中最常见的是hPIV3(46%),其次是hPIV1(27%),hPIV4(16%)和hPIV2(11%)。所有hPIV类型的中位年龄为2岁。 hPIV1和hPIV2的男性略大于女性,hPIV3的分布均等,而hPIV4的女性略多于男性。 hPIV1和hPIV2具有最高的人群比例,而hPIV3和hPIV4具有最高的肺炎比例。在hPIV4病例中,疾病的分布是;肺炎(21%,95%CI 17.1-25.7),细支气管炎(18%,95%CI 14.3-22.5),人群(2%,95%CI 0.8-3.9),肺炎,细支气管炎的混合病或臀部病(4%,95%CI 2.5–7.0)或其他呼吸系统疾病(54%,95%CI 49.1–59.6)。结论我们使用实验室和行政数据对hPIV1-4与人群,细支气管炎和肺炎的关系进行了描述性分析。在我们的人群中,hPIV4与毛细支气管炎和肺炎的相关性更高,而与群体性哮喘的相关性较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号